Table 1.

Clinical results of ipilimumab in combination with chemotherapy in patients with chemotherapy-naive advanced (Stage IIIB or IV) NSCLC [9]

	Phased ipilimumab	Concurrent ipilimumab	Chemotherapy control
Median time to immune-related progression	5.7 months	5.5 months	4.6 months
HR and P value versus control	HR = 0.72, 0.05	HR = 0.81, 0.13
Median progression-free survival (WHO criteria)	5.1 months	4.1 months	4.2 months
HR and P value versus control	HR = 0.69, 0.02	HR = 0.88, 0.25
OS, median	12.2 months	9.7 months	8.3 months
P value versus control	HR = 0.87, 0.23	HR = 0.99, 0.48
OS at 1 year	50 %	42 %	39 %

HR hazard ratio, OS overall survival, WHO World Health Organization